Business
Natera Reports First Quarter 2026 Financial Results
AUSTIN, Texas, May 07, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2026.
About this update from Oncology Pharma Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":200,"height":200,"url":"https://media.zenfs.com/en/business-wire.com/dbf5b7fe8002c10dc405e6d2c24d8131"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ImTgDtBUv4mt42RHvP73Ig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTM2MA--/https://media.zenfs.com/en/business-wire.com/dbf5b7fe8002c10dc405e6d2c24d8131","width":200,"height":200},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/ImTgDtBUv4mt42RHvP73Ig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTM2MA--/https://media.zenfs.com/en/business-wire.com/dbf5b7fe8002c10dc405e6d2c24d8131","width":200,"height":200}},"lazy":false},{"type":"text","content":"AUSTIN, Texas, May 07, 2026--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2026.","length":209,"tagName":"p"},{"type":"text","content":"Recent Financial Highlights","length":27,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Generated total revenues of $696.6 million in the first quarter of 2026, compared to $501.8 million in the first quarter of 2025, an increase of 38.8%.","length":151,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Generated a gross margin1 of 64.7% in the first quarter of 2026, compared to a gross margin1 of 63.1% in the first quarter of 2025.","length":131,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Processed approximately 1,013,600 tests in the first quarter of 2026, compared to approximately 855,100 tests in the first quarter of 2025, an increase of 18.5%. Women’s Health generated the second highest quarterly unit growth since 2019 and Oncology delivered another record quarter for volume growth.","length":303,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Processed approximately 258,900 oncology tests in the first quarter of 2026, compared to approximately 167,700 in the first quarter of 2025, an increase of 54.4%.","length":162,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Achieved positive cash inflow of approximately $11.8 million2 in the first quarter of 2026.","length":91,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Raising 2026 annual revenue guidance...